Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,187
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Placebo (Vehicle) for investigational DFL24498, Isocyclosporin A, DEXAMETHASONE
Dompe' Farmaceutici S.p.A.
Atopic Keratoconjunctivitis
1 trial -
TROPICAMIDE, Vehicle for cenegermin drug product, COLIROFTA ANESTÉSICO DOBLE 1 MG/ML + 4 MG/ML COLIRIO EN SOLUCIÓN, OXERVATE 20 micrograms/ml eye drops, solution
Dompe' Farmaceutici S.p.A.
Persistent Corneal Epithelial Defect (PCED)
1 trial -
Cenegermin, The placebo for investigational lyophilized cenegermin Drug Product is the same as the Drug Product with the exception that it does not contain cenegermin.
Dompe' Farmaceutici S.p.A.
Spastic Cerebral Palsy
1 trial -
Ladarixin, Placebo to match Ladarixin
Dompe' Farmaceutici S.p.A.
Recent onset Type 1 Diabetes
1 trial -
Reparixin, Placebo - Tablet for oral use
Dompe' Farmaceutici S.p.A.
Acute Respiratory Distress Syndrome
1 trial -
TACHIPIRINA 500 mg compresse, OKi 80 mg granulato per soluzione orale, KLS-GABA 40mg-17mg, KLS-GABA 80mg-34mg
Dompe' Farmaceutici S.p.A.
Chronic low back pain
1 trial -
Vehicle (Isocyclosporin A 0 mg/mL, 0%), Isocyclosporin A, TROPICAMIDE , SODIUM CHLORIDE , OXYBUPROCAINE
Dompe' Farmaceutici S.p.A.
Atopic keratoconjunctivitis (AKC)
1 trial -
Vehicle, Cenegermin
Dompe' Farmaceutici S.p.A.
Subacute Moderate to Severe Traumatic Brain Injury (TBI)
1 trial -
rhNGF New Lyo Formulation, OXYBUPROCAINE , SODIUM CHLORIDE , rhNGF New Lyo Formulation, The placebo consists of a lyophilized product packaged in 2R siliconized glass class I vials closed with a stopper and a flip off cap and administered after reconstitution with 2mL of diluent contained into a 2R glass class I vials closed with a stopper and a flip off cap. The diluent consists of DMSO, Sesame Extract 98%, Kollifor HS 0.15%, Sodium Chloride, Water For Injection. The product is reconstituted using an ada
Dompe' Farmaceutici S.p.A.
Dry Eye
1 trial -
A single and multiple ascending dose study of topical ladarixin ophthalmic solution in healthy volunteers
Dompe' Farmaceutici S.p.A.
Ocular inflammatory conditions
1 trial -
Food effect and single- and multiple-ascending dose clinical trial of DF2755A in healthy participants
Dompe' Farmaceutici S.p.A.
interstitial cystitis/bladder pain syndrome
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources